RBC Upgrades Aveanna Healthcare (AVAH) to Outperform

Aveanna Healthcare Holdings Inc. (NASDAQ) Receives 'Outperform' Upgrade Amid Strategic Transformation

• RBC Capital has upgraded Aveanna Healthcare Holdings Inc. to an "Outperform" rating, signaling increased confidence in the company's future prospects.
• The company has significantly reduced its financial leverage, improving from over 11 times at the end of 2022 to under 3.8 times by Q1 2023.
• Wall Street analysts predict a potential 50.7% upside for Aveanna Healthcare Holdings Inc., with a consensus price target of $10.05.

Aveanna Healthcare Holdings Inc. (NASDAQ) is a diversified home healthcare services provider in the United States. The company offers a range of services, with a focus on specialized pediatric home care. It recently expanded its operations by completing the acquisition of Family First Homecare, which has 27 locations across seven states. Aveanna Healthcare Holdings Inc. has a market capitalization of approximately $1.41 billion.

RBC Capital has upgraded its rating for Aveanna Healthcare Holdings Inc. to "Outperform" from its previous "Sector Perform" rating. This change occurred when the stock was priced at $6.47. The upgrade suggests a more positive investment outlook on the company's financial performance and future prospects, signaling increased confidence from the investment bank.

This positive view is supported by the company's recent strategic actions. Since early 2023, Aveanna Healthcare Holdings Inc. has undergone a significant strategic transformation. A key achievement is the reduction of its financial leverage, which measures debt against earnings. This ratio improved significantly, falling from over 11 times at the end of 2022 to under 3.8 times by the first quarter's end.

Following its recent acquisition, the company raised its 2026 growth outlook and is now targeting 7% to 10% revenue growth. This goal is backed by a strong history, as Aveanna Healthcare Holdings Inc. has achieved a nearly 10% compound annual growth rate in revenue over the last six years, driven mainly by internal expansion.

Other Wall Street analyst ratings share this optimism. As highlighted by Zacks Investment Research, market analysts predict a potential 50.7% upside for Aveanna Healthcare Holdings Inc. The consensus price target is $10.05, based on ten short-term targets that range from a low of $8.00 to a high of $13.00.